Animal models of Alzheimer disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 11, 2012, Pages

  LaFerla, Frank M ^a   Green, Kim N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; GAMMA SECRETASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRESENILIN; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DOWN SYNDROME; FAMILIAL DISEASE; GENE MUTATION; INFLAMMATION; MYELINATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALIA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; TAU PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84886678332     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006320     Document Type: Article

References (87)

1. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, et al. 2008. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59: 43-55.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
3. Beel AJ, Sanders CR. 2008. Substrate specificity of γ-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311-1334.
4. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. 2005. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45: 675-688.
5. Bloch L, Sineshchekova O, Reichenbach D, Reiss K, Saftig P, Kuro-o M, KaetherC. 2009. Klotho is a substrate for α-, β-and γ-secretase. FEBS Lett 583: 3221-3224.
6. Blurton-Jones M, LaFerla FM. 2006. Pathways by which Aβ facilitates tau pathology. Curr Alzheimer Res 3: 437-448.
7. Boche D, Denham N, Holmes C, Nicoll JA. 2010. Neuropathology after active Aβ42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120: 369-384.
8. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, VingtdeuxV, van de Steeg E, Ret G, Canton T, et al. 2004. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165: 1289-1300.
9. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasamudram T, Bilcer G, Ghosh AK, et al. 2004. In vivo inhibition of Aβ production by memapsin 2 (β-secretase) inhibitors. J Neurochem 89: 1409-1416.
10. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. 2001. Intrahippocampal LPS injections reduce Aβ load in APP + PS1 transgenic mice. Neurobiol Aging 22: 1007-1012.
11. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. 2005. Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 280: 30797-30806.
12. Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, Nguyen T, Wong PC, Price DL, Slusher BS, Griffin JW. 2011. Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci 31: 5744-5754.
13. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, et al. 2010. PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. J Alzheimers Dis 20: 509-516.
14. Findeis MA. 2007. The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol Ther 116: 266-286.
15. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, et al. 2010. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30: 11157-11166.
16. Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, IttnerLM. 2007. A decade of tau transgenic animal models and beyond. Brain Pathol 17: 91-103.
17. Green KN, LaFerla FM. 2008. Linking calcium to Aβ and Alzheimer's disease. Neuron 59: 190-194.
18. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. 2001. Intraneuronal aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492.
19. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
20. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, et al. 2002. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for α-secretase activity in fibroblasts. Human Mol Genet 11: 2615-2624.
21. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, et al. 1999. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci 96: 11872-11877.
22. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68: 1067-1081.
23. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. 2006. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9: 1520-1525.
24. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R. 2008. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J22: 2970-2980.
25. Huang WH, Sheng R, Hu YZ. 2009. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. Curr Med Chem 16: 1806-1820.
26. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, et al. 1999. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci 14: 419-427.
27. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, et al. 2007. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. J Neurochem 100: 802-809.
28. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, ChiengBC, Christie MJ, Napier IA, et al. 2010. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
29. Keller JN, Hanni KB, Markesbery WR. 2000. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439.
30. v1. 1 levels in BACE1-null mice. J Biol Chem 286: 8106-8116.
31. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. 2005. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25: 8843-8853.
32. Kokubo H, Kayed R, Glabe CG, Yamaguchi H. 2005. Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res 1031: 222-228.
33. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, MurdochGH, Ball MJ, Roher AE. 1996. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077-4081.
34. LaFerla FM, Green KN, Oddo S. 2007. Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 8: 499-509.
35. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, ChiangHC, Xu G, Koliatsos VE, et al. 2005. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693-11709.
36. Lee DC, Sunnarborg SW, Hinkle CL, Myers TJ, Stevenson MY, Russell WE, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, et al. 2003. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann NY Acad Sci 995: 22-38.
37. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, et al. 2010. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141: 1146-1158.
38. Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, et al. 2010. Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application. Bioorg Med Chem Lett 20: 603-607.
39. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491.
40. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, ZhangJ, Gong Y, et al. 2001. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nature Neurosci 4: 231-232.
41. Marighetto A, Valerio S, Desmedt A, Philippin JN, Trocme-Thibierge C, MorainP. 2008. Comparative effects of the α7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacol (Berl) 197: 499-508.
42. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, MurphyMP, Beard J, Das P, et al. 2005. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191-199.
43. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, et al. 2006. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature Med 12: 801-808.
44. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, CalverAR, Cilia J, Cluderay JE, Crook B, Davis JB, et al. 2007. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321: 1032-1045.
45. Mehlhorn G, Hollborn M, Schliebs R. 2000. Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 18: 423-431.
46. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, et al. 2003. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 6: 370-377.
47. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, KilgerE, Neuenschwander A, Abramowski D, Frey P, Jaton AL, et al. 2006. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313: 1781-1784.
48. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de CalignonA, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. 2008. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724.
49. Morgan D. 2006. Immunotherapy for Alzheimer's disease. J Alzheimers Dis 9: 425-432.
50. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA. 2002. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid 9: 88-102.
51. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, Litchfield S, SmithA, Barnetson L, Smith AD. 1995. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: Correlations using three sets of neuropathological criteria. Dementia 6: 21-31.
52. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, BuxbaumJD. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
53. Neely KM, Green KN, LaFerla FM. 2011. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci 31: 2781-2791.
54. Oddo S. 2008. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 12: 363-373.
55. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. 2003a. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070.
56. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. 2003b. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron 39: 409-421.
57. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. 2004. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332.
58. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. 2004. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27-33.
59. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, YuGQ, Kreitzer A, et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711.
60. Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, FengY, Palmeri A, Landry DW, et al. 2009. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model. J Neurosci 29: 8075-8086.
61. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, et al. 2001. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Human Mol Genet 10: 1317-1324.
62. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, YuGQ, Mucke L. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
63. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, et al. 2009. First demonstration of cerebrospinal fluid and plasma A β lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328: 131-140.
64. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. 2008. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci 105: 5585-5590.
65. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
66. Schor NF. 2011. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69: 237-239.
67. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. 1997. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89: 629-639.
68. Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, et al. 2011. Tau protein is required for amyloid β-induced impairment of hippocampal long-term potentiation. J Neurosci 31: 1688-1692.
69. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. 1999. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402: 537-540.
70. Steele M, Stuchbury G, Munch G. 2007. The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 42: 28-36.
71. Takei Y, Teng J, Harada A, Hirokawa N. 2000. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol 150: 989-1000.
72. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
73. Tomic JL, Pensalfini A, Head E, Glabe CG. 2009. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358.
74. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. 1999. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
75. Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, et al. 2009. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 52: 7946-7949.
76. Walsh DM, Selkoe DJ. 2007. A β oligomers-A decade of discovery. J Neurochem 101: 1172-1184.
77. Wang J, Dickson DW, Trojanowski JQ, Lee VM. 1999. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158: 328-337.
78. Webster SD, Tenner AJ, Poulos TL, Cribbs DH. 1999. The mouse C1q A-chain sequence alters β-amyloid-induced complement activation. Neurobiol Aging 20: 297-304.
79. Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, GharkholonareheN, Vitek MP, Colton CA. 2008. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 28: 1537-1545.
80. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. 2006. Control of peripheral nerve myelination by the β-secretase BACE1. Science 314: 664-666.
81. Woltjer RL, Sonnen JA, Sokal I, Rung LG, Yang W, Kjerulf JD, Klingert D, JohnsonC, Rhew I, Tsuang D, et al. 2009. Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly. Brain Pathol 19: 365-374.
82. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. 2005. β Subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J Biol Chem 280: 23009-23017.
83. Wyss-Coray T, Mucke L. 2002. Inflammation in neurodegenerative disease-A double-edged sword. Neuron 35: 419-432.
84. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerlaFM. 2007. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 27: 11925-11933.
85. Yang F, Ueda K, Chen P, Ashe KH, Cole GM. 2000. Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res 853: 381-383.
86. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H. 2007. Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci 104: 10613-10618.
87. Zheng H, Jiang M, Trumbauer ME, Hopkins R, Sirinathsinghji DJ, Stevens KA, Conner MW, Slunt HH, Sisodia SS, Chen HY, et al. 1996. Mice deficient for the amyloid precursor protein gene. Ann NY Acad Sci 777: 421-426.